OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Cancer is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)

Article	Citations
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy	913
Targeting ferroptosis as a vulnerability in cancer	843
Cancer metabolism: looking forward	792
Therapeutic cancer vaccines	731
Systemic immunity in cancer	676
RNA in cancer	662
A compendium of mutational cancer driver genes	658
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion	636
Connecting copper and cancer: from transition metal signalling to metalloplasia	597
Neutrophil diversity and plasticity in tumour progression and therapy	593
The role of ROS in tumour development and progression	589
Endoplasmic reticulum stress signals in the tumour and its microenvironment	567
The rediscovery of platinum-based cancer therapy	494
The metabolism of cancer cells during metastasis	487
The matrix in cancer	485
Recent advances and discoveries in the mechanisms and functions of CAR T cells	484
Metabolism of immune cells in cancer	433
Long noncoding RNAs in cancer metastasis	367
Interleukins in cancer: from biology to therapy	362
Advances in bladder cancer biology and therapy	349
Exploiting senescence for the treatment of cancer	328
The evolving translational potential of small extracellular vesicles in cancer	319
Non-genetic mechanisms of therapeutic resistance in cancer	312
Linking EMT programmes to normal and neoplastic epithelial stem cells	297
Advancing targeted protein degradation for cancer therapy	276

Cancer stem cell–immune cell crosstalk in tumour progression	262
Natural killer cells in antitumour adoptive cell immunotherapy	260
The immunological and metabolic landscape in primary and metastatic liver cancer	246
Mutations and mechanisms of WNT pathway tumour suppressors in cancer	244
Targeting DNA damage response pathways in cancer	219
Cancer progression and the invisible phase of metastatic colonization	214
Autophagy in tumour immunity and therapy	205
Harnessing multimodal data integration to advance precision oncology	204
The language of chromatin modification in human cancers	202
CRISPR in cancer biology and therapy	189
Designing deep learning studies in cancer diagnostics	187
Tumour fatty acid metabolism in the context of therapy resistance and obesity	178
A new dawn for eosinophils in the tumour microenvironment	174
Targeting CDK4 and CDK6 in cancer	174
The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs	173
Targeting FAK in anticancer combination therapies	168
Genetic and non-genetic clonal diversity in cancer evolution	166
Cancer nanomedicine	162
Targeting the DNA damage response in immuno-oncology: developments and opportunities	160
Programmed death ligand 1 signals in cancer cells	157
MYC protein interactors in gene transcription and cancer	153
Antitumour immunity regulated by aberrant ERBB family signalling	152
Overcoming TGFβ-mediated immune evasion in cancer	150
Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities	149
Sex disparities matter in cancer development and therapy	148
Mutational signatures: emerging concepts, caveats and clinical applications	148
Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data	143
Liquid–liquid phase separation drives cellular function and dysfunction in cancer	140
Towards targeting of shared mechanisms of cancer metastasis and therapy resistance	140
Clonal expansion in non-cancer tissues	138
A timeline of tumour-associated macrophage biology	136
2-Oxoglutarate-dependent dioxygenases in cancer	128
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer	128
Hyperinsulinaemia in cancer	127
The epigenomics of sarcoma	127
Mitochondrial DNA variation and cancer	121
The plasticity of mRNA translation during cancer progression and therapy resistance	120
Stress and cancer: mechanisms, significance and future directions	119
Aneuploidy as a promoter and suppressor of malignant growth	114
Improving human cancer therapy through the evaluation of pet dogs	111
RNA splicing dysregulation and the hallmarks of cancer	108
Mechanisms of immune activation and regulation: lessons from melanoma	108
Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment	107
Polyamines in cancer: integrating organismal metabolism and antitumour immunity	106
Advances in germline predisposition to acute leukaemias and myeloid neoplasms	98
Artificial intelligence in cancer research, diagnosis and therapy	98
Synthetic biomarkers: a twenty-first century path to early cancer detection	97
Glial and myeloid heterogeneity in the brain tumour microenvironment	96
mRNA-based cancer therapeutics	95
Big data in basic and translational cancer research	94

Cancer proteogenomics: current impact and future prospects	92
Decoding leader cells in collective cancer invasion	89
Dynamics and specificities of T cells in cancer immunotherapy	89
Biology, vulnerabilities and clinical applications of circulating tumour cells	88
Smokeless tobacco and cigarette smoking: chemical mechanisms and cancer prevention	85
Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies	85
Leukaemia: a model metastatic disease	81
Mapping the genomic diaspora of gastric cancer	80
Targeting the gut microbiota for cancer therapy	79
The coming decade in precision oncology: six riddles	74
Therapeutic targeting of tumour myeloid cells	71
Nucleotide metabolism: a pan-cancer metabolic dependency	69
STAT proteins in cancer: orchestration of metabolism	67
Metabolic rivalry: circadian homeostasis and tumorigenesis	67
Developing dietary interventions as therapy for cancer	65
Targeting transcription cycles in cancer	64
Non-coding driver mutations in human cancer	63
Acetyl-CoA metabolism in cancer	61
Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment	60
Mechanisms driving the immunoregulatory function of cancer cells	59
Context-dependent functions of pattern recognition receptors in cancer	57
Tissue clearing to examine tumour complexity in three dimensions	56
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation	56
Evolving cancer–niche interactions and therapeutic targets during bone metastasis	54
Nonsense-mediated RNA decay: an emerging modulator of malignancy	53
Disconnecting multicellular networks in brain tumours	51
Brain cancer stem cells: resilience through adaptive plasticity and hierarchical heterogeneity	51
In vivo functional screening for systems-level integrative cancer genomics	46
Leveraging the replication stress response to optimize cancer therapy	45
Tumour–host interactions through the lens of Drosophila	45
Bacteria in cancer initiation, promotion and progression	45
Insights into recent findings and clinical application of YAP and TAZ in cancer	45
Remodelling of the tumour microenvironment by the kallikrein-related peptidases	43
Solid tumours hijack the histone variant network	40